Education
About Us
Working with TipRanks
Follow Us
Immutep (IMMP)
NASDAQ:IMMP
IMMP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.65 - $3.34
Previous CloseN/A
Volume50.42K
Average Volume (3M)71.67K
Market Cap
$283.54M
Enterprise Value$124.09M
Total Cash (Recent Filing)AU$103.73M
Total Debt (Recent Filing)AU$1.61M
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Aug 27, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding145,558,960
10 Day Avg. Volume59,302
30 Day Avg. Volume71,669
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$12.00Price Target Upside538.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Immutep News
PremiumCompany Announcements
Immutep Reports Increased Revenue Amid Growing R&D Costs
PremiumCompany Announcements
Immutep Reports Increased Revenue Amid Rising R&D Costs
PremiumCompany Announcements
Immutep Advances to Phase III with Key Approvals and Promising Trial Results
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessImmutep reported positive updated data from cohort B of the P2b TACTI-003 study evaluating efti + Keytruda in 1L head & neck cancer with negative PD-L1 expression, showing promising results.
Market OpportunityThe TACTI-004 trial could open up a very large market opportunity for IMMP, as it will be enrolling first line squamous and non-squamous NSCLC patients who are unselected for PD-L1 expression.
Survival DataImmutep announced positive survival data from the ongoing P1 INSIGHT-003 study in 1L metastatic non-small cell lung cancer.
Bears Say
Competitive LandscapeThe 1L metastatic HNSCC space has become very competitive.
Complex Data InterpretationHe viewed the data as 'confusing' as it could not be 'crisply explained' since pembro monotherapy overperformed historic expectations.
---
Ownership Overview
―
Insiders
0.02% Mutual Funds
0.58% Other Institutional Investors
98.92% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IMMP FAQ
What was Immutep’s price range in the past 12 months?
Immutep lowest stock price was $1.65 and its highest was $3.33 in the past 12 months.
What is Immutep’s market cap?
Immutep’s market cap is $283.54M.
When is Immutep’s upcoming earnings report date?
Immutep’s upcoming earnings report date is Aug 27, 2025 which is in 155 days.
How were Immutep’s earnings last quarter?
Immutep released its earnings results on Feb 26, 2025. The company reported -$0.096 earnings per share for the quarter, beating the consensus estimate of -$0.136 by $0.04.
Is Immutep overvalued?
According to Wall Street analysts Immutep’s price is currently Undervalued.
Does Immutep pay dividends?
Immutep does not currently pay dividends.
What is Immutep’s EPS estimate?
Immutep’s EPS estimate is -0.13.
How many shares outstanding does Immutep have?
Immutep has 145,558,960 shares outstanding.
What happened to Immutep’s price movement after its last earnings report?
Immutep reported an EPS of -$0.096 in its last earnings report, beating expectations of -$0.136. Following the earnings report the stock price went up 1.064%.
Which hedge fund is a major shareholder of Immutep?
Currently, no hedge funds are holding shares in IMMP
---
Immutep Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (538.30% Upside)
$12.00 (538.30% Upside)
Blogger Sentiment
Bullish
IMMP Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 564.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 14.5%
Last 30 Days ▼ 14.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.09%
12-Months-Change
Fundamentals
Return on Equity
-31.16%
Trailing 12-Months
Asset Growth
33.65%
Trailing 12-Months
Company Description
Immutep
Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. Its product is IMP321, which involves in clinical development for the treatment of breast cancer and melanoma. The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.
---
IMMP Stock 12 Month Forecast
Average Price Target
$12.00
▲(538.30% Upside)
Technical Analysis
Best Analysts Covering IMMP
1 Year
1 Year Success Rate
0/11 ratings generated profit
1 Year Average Return
-36.68%
reiterated a buy rating 6 months ago
Copying Naureen Quibria's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -36.68% per trade.
---